Objective To implement the disease prevention and control strategy of being ^"proactive and grassroots-focused,^" and to enhance the overall effectiveness of general hospitals in the tertiary prevention of cervical cancer, this consensus aims to provide an actionable guiding framework for the standardized construction of ^"Integrated Outpatient Clinics for Cervical Cancer Prevention and Control^" in general hospitals at all levels. Methods This consensus systematically elaborates on the specific elements for establishing such integrated clinics and formulates the corresponding standards. Results It is anticipated that the consensus will promote the establishment of standardized, homogeneous, and high-efficiency frontline positions for cervical cancer prevention and control within general hospitals, thereby contributing to the strategic vision of accelerating the elimination of cervical cancer. Conclusion The formulation and promotion of the consensus aim to provide robust clinical practice support for accelerating the realization of China's strategic vision of eliminating cervical cancer.

OBJECTIVE To promote the rational use of phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt）/ mammalian target of rapamycin （mTOR） inhibitors in breast cancer treatment and provide guidance for pharmacists to implement homogeneous medication therapy management. METHODS A multidisciplinary panel comprising content experts （clinical medicine， pharmacy） and methodological experts （evidence-based medicine， statistics， medical ethics） was assembled using the Nominal Group Technique. A draft consensus was developed through systematic literature retrieval， analysis， and synthesis. External reviewers evaluated the draft via questionnaire-based feedback and revisions were incorporated to finalize the consensus. RESULTS This consensus framework focuses on the medication therapy management process of PI3K/Akt/mTOR inhibitors with information collection， treatment regimen evaluation and pharmaceutical intervention structure modules. Seven critical issues and eight evidence-based recommendations were addressed， including efficacy assessment， drug selection， safety， drug interactions， and adherence. CONCLUSION This consensus offers comprehensive medication guidance on PI3K/Akt/mTOR inhibitors in the treatment of breast cancer for pharmacists， aiming to enhance therapeutic effectiveness in patients， reduce the incidence of adverse reactions， and ensure the safe and effective use of medications.